Covid-19
Britain investigates AstraZeneca-Alexion deal on competition concerns
Britain’s Competition and Markets Authority (CMA) has started its investigation into whether AstraZeneca’s takeover of Alexion Pharmaceuticals can reduce competition for products and services in the United Kingdom or any other markets.
The British competition regulator invites comments on the transaction from any interested party to assist the CMA with the assessment.
The comments should be reached by June 3.
In December 2020, British drug manufacturer AstraZeneca agreed to buy Alexion Pharmaceuticals for 175 dollars per share in cash and stock, valuing the Boston-based company at 39 billion dollars.
-
News5 days agoWidow of late investigative broadcaster Kola Olawuyi dies
-
Crime5 days agoOutrage as NYSC doctor allegedly dies after delay in approving sick leave
-
Latest4 days agoOne killed as ethnic clash erupts in Ibadan following reported overnight stabbing (video)
-
Latest5 days agoLagos arrests 396 beggars in fresh crackdown on street begging (Video)
-
Energy6 days agoGas flaring takes toll on children, residents in Rivers oil-producing communities
-
Aviation5 days agoNIS issues updated guidelines for contactless passport renewal for Nigerians abroad
-
Aviation6 days agoCould you prove that bag is yours? The precautions that could protect you from a travel nightmare
-
Latest6 days agoJonathan rejects political bribery allegation ahead of 2027 elections